Skip to search formSkip to main contentSkip to account menu

rociletinib

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AcrylamidesPyrimidines

Narrower (1)

CO-1686

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Beware the TIGER‐X's stripes: rapid cataract formation in patients taking Rociletinib
Non-small cell lung cancer (NSCLC) is increasingly being treated with molecularly targeted therapy, as opposed to empirically… 
2017
2017
Medicinal Chemistry Case History: Osimertinib (AZD9291)
2016
2016
Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.
9001Background: Rociletinib is an oral inhibitor of mutant EGFR, including T790M. We compared EGFR mutation detection in… 
2016
2016
Actualités sur les thérapies ciblées dans les cancers bronchiques non à petites cellules, hors immunothérapie
2016
2016
Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.
9000Background: The third generation EGFR tyrosine kinase inhibitor (TKI) rociletinib has demonstrated activity in non-small cell… 
Review
2016
Review
2016
[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
2015
2015
TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy…
TPS8109 Background: Rociletinib is a small molecule inhibitor that selectively targets mutant EGFR and has been shown in… 
2015
2015
Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third Generation EGFR Inhibitor RUNNING TITLE: T790 Heterogeneity in…
Zofia Piotrowska Massachusetts General Hospital, Boston, MA Matthew J. Niederst Massachusetts General Hospital, Boston, MA Chris… 
2015
2015
Abstract 3595:In vivoacquired resistance to the mutant EGFR inhibitor Rociletinib (CO-1686) is associated with activation of the c-MET pathway
Rociletinib is a novel, oral, targeted irreversible inhibitor of the cancer-causing mutant forms of EGFR currently being studied… 
2014
2014
10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)